Spring,

I appologize for not getting to your question sooner...I'm still running around the USA meeting with institutional investors, etc. Essentially, these are "safe harbor" statements, which I believe were probably taken from Pluristem's SEC 10K (Annual Report). Some of them are fairly generic and applicable to many companies, but some are more unique to Pluristem...including any problems associated with Pluristem's Bioreactor System or the political/military stability in Israel.

If you want me to addres any particular risk, please let me know. I encourage everyone to discuss and learn about Pluristem's opportunities and risks before investing.

Please note a significant possibility for Pluristem on page 13 of the Crystal overview. There are 16 different disease categories and over 80 diseases (I counted 86) that could be treated with Stem Cell Transplantation. "{Based on Pluristem's belief that its proprietary PLX cells are unique and possess favorable immunologic
characteristics, the Company expects to investigate the use of these expanded mesenchymal stem cells
in the treatment of a variety of diseases that could target markets estimated to exceed $30 billion. These
diseases include degenerative disorders such as Parkinson's disease, diabetes, ischemic diseases such
as stroke, and a variety of malignancies." (page 6).

Very Respectfully,

Craig